Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-17-0552
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Molecular Imaging of C-Met Tyrosine Kinase Activity

Analytical Biochemistry
BiochemistryCell BiologyMolecular BiologyBiophysics
2011English

From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-Tumor and Anti-Angiogenic Agents

Oncogene
Cancer ResearchGeneticsMolecular Biology
2000English

Discovery of New Thiophene, Pyrazole, Isoxazole Derivatives as Antitumor, C-Met, Tyrosine Kinase and Pim-1 Kinase Inhibitors

Bulletin of the Chemical Society of Ethiopia
Chemistry
2018English

Novel Bruton's Tyrosine Kinase Inhibitors Currently in Development

OncoTargets and Therapy
OncologyPharmacology
2013English

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Tyrosine Kinase Inhibitors for Diabetes

Science-Business eXchange
2008English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance

Cancers
Cancer ResearchOncology
2018English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy